Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company announced its 2Q2025 financial results and noted that Phase 1B testing results on Gemini are expected later this quarter. Investors should take a look at REVB before the positive results start coming in.
